Log In
Print
BCIQ
Print
Print this Print this
 

Janumet XR, sitagliptin/metformin

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionFixed-dose combination of Januvia sitagliptin phosphate plus extended-release metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26) ; AMP-activated protein kinase (AMPK)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today